Development of ICT01, a first-in-class, anti-BTN3A antibody for activating Vγ9Vδ2 T cell–mediated antitumor immune response

ICT01, a humanized BTN3A mAb, activates Vγ9Vδ2 T cell antitumor immunity and is well tolerated and pharmacodynamically active in patients.